Atossa Therapeutics (NASDAQ:ATOS) Issues Earnings Results

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) issued its quarterly earnings data on Monday. The company reported ($0.06) earnings per share for the quarter, Yahoo Finance reports.

Atossa Therapeutics Stock Performance

Shares of ATOS stock opened at $1.84 on Wednesday. Atossa Therapeutics has a one year low of $0.59 and a one year high of $2.11. The company’s fifty day moving average price is $1.17 and its 200-day moving average price is $0.90.

Wall Street Analyst Weigh In

Several research firms have weighed in on ATOS. Cantor Fitzgerald reiterated an “overweight” rating on shares of Atossa Therapeutics in a research report on Friday, January 12th. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Atossa Therapeutics in a research report on Tuesday.

Read Our Latest Report on ATOS

Institutional Trading of Atossa Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ATOS. JPMorgan Chase & Co. grew its stake in Atossa Therapeutics by 27.0% during the first quarter. JPMorgan Chase & Co. now owns 54,960 shares of the company’s stock valued at $69,000 after acquiring an additional 11,683 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Atossa Therapeutics by 4.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 313,912 shares of the company’s stock valued at $393,000 after acquiring an additional 14,481 shares in the last quarter. Renaissance Technologies LLC grew its stake in Atossa Therapeutics by 79.5% during the first quarter. Renaissance Technologies LLC now owns 2,100,492 shares of the company’s stock valued at $2,626,000 after acquiring an additional 930,152 shares in the last quarter. State Street Corp grew its stake in Atossa Therapeutics by 4.2% during the first quarter. State Street Corp now owns 2,233,010 shares of the company’s stock valued at $2,791,000 after acquiring an additional 90,960 shares in the last quarter. Finally, First Republic Investment Management Inc. grew its stake in Atossa Therapeutics by 79.8% during the first quarter. First Republic Investment Management Inc. now owns 25,167 shares of the company’s stock valued at $31,000 after acquiring an additional 11,167 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors.

Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Featured Stories

Earnings History for Atossa Therapeutics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.